feedzop-word-mark-logo
searchLogin
Feedzop
homeFor YouUnited StatesUnited States
You
bookmarksYour BookmarkshashtagYour Topics
Trending
Terms of UsePrivacy PolicyAboutJobsPartner With Us

© 2026 Advergame Technologies Pvt. Ltd. ("ATPL"). Gamezop ® & Quizzop ® are registered trademarks of ATPL.

Gamezop is a plug-and-play gaming platform that any app or website can integrate to bring casual gaming for its users. Gamezop also operates Quizzop, a quizzing platform, that digital products can add as a trivia section.

Over 5,000 products from more than 70 countries have integrated Gamezop and Quizzop. These include Amazon, Samsung Internet, Snap, Tata Play, AccuWeather, Paytm, Gulf News, and Branch.

Games and trivia increase user engagement significantly within all kinds of apps and websites, besides opening a new stream of advertising revenue. Gamezop and Quizzop take 30 minutes to integrate and can be used for free: both by the products integrating them and end users

Increase ad revenue and engagement on your app / website with games, quizzes, astrology, and cricket content. Visit: business.gamezop.com

Property Code: 5571

trending

PFC REC merger approved

trending

Tata Steel share price surges

trending

ITC stock market stability

trending

SBI share price jumps

trending

ITA Airways promotes Olympics

trending

Brandon McMullen scores 41

trending

Scotland seek Italy revenge

trending

Zimbabwe vs Oman T20

trending

Kruthik Krishna proves mettle

Home / Health / Bihar Fights Filariasis: 8.97 Crore Targeted!

Bihar Fights Filariasis: 8.97 Crore Targeted!

9 Feb

Summary

  • Bihar launches an 18-day campaign to treat 8.97 crore people.
  • Managing adverse drug reactions is crucial for public confidence.
  • Yearly medication for five years can significantly reduce transmission.
Bihar Fights Filariasis: 8.97 Crore Targeted!

Bihar is embarking on a significant public health initiative with an 18-day Mass Drug Administration (MDA) campaign to combat lymphatic filariasis. This effort aims to reach approximately 8.97 crore individuals across 34 of the state's 38 districts, commencing on Tuesday and concluding on February 28. The campaign's success hinges on effectively managing potential adverse drug reactions (ADRs) to sustain public confidence and ensure maximum participation.

Anti-filarial medicines, including Albendazole, Diethylcarbamazine (DEC), and Ivermectin, will be administered under supervision. While reactions like nausea and headache are generally mild, they can deter people from taking the drugs. Special mega camps are planned, including one on February 11 targeting 2 crore doses for members of women's self-help groups. Trained teams will conduct household visits to ensure supervised consumption, with special school booths planned for the final three days.

Addressing drug refusal is also a key challenge, though past interventions have shown success in converting refusals to acceptance. Health officials emphasize that consistent annual medication for five years is vital for significantly reducing disease transmission. Bihar accounts for a substantial portion of India's filariasis cases, making this campaign critical for national elimination goals by 2027.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
Bihar is conducting an 18-day Mass Drug Administration (MDA) campaign, aiming to administer anti-filarial medicines to 8.97 crore people across 34 districts.
Managing adverse drug reactions is crucial for maintaining public confidence and ensuring high drug uptake during the Mass Drug Administration (MDA) campaign.
Taking anti-filarial medication once a year for five consecutive years can significantly reduce disease transmission in Bihar.

Read more news on

Healthside-arrow
•

You may also like

Cancer Drug Duty Cut: Relief or Mere Drop?

14 hours ago • 4 reads

article image

Leprosy's Cure Emerged From Dye Industry

31 Jan • 40 reads

article image

Addiction Warning For Common Pain, Anxiety Meds

12 Jan • 130 reads

article image

Pulmocide Trial Halted: Higher Mortality Rate Found

9 Jan • 112 reads

article image

Biotech Battles GSK Over Cancer Drug Royalties

9 Jan • 181 reads

article image